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A B S T R A C T
The October 2020 Global TB report reviews TB control strategies and United Nations (UN) targets set in
the political declaration at the September 2018 UN General Assembly high-level meeting on TB held in
New York. Progress in TB care and prevention has been very slow. In 2019, TB remained the most common
cause of death from a single infectious pathogen. Globally, an estimated 10.0 million people developed TB
disease in 2019, and there were an estimated 1.2 million TB deaths among HIV-negative people and an
additional 208, 000 deaths among people living with HIV. Adults accounted for 88% and children for 12%
of people with TB. The WHO regions of South-East Asia (44%), Africa (25%), and the Western Pacific (18%)
had the most people with TB. Eight countries accounted for two thirds of the global total: India (26%),
* Corresponding author at: Department of Clinical Sciences, Liverpool School of Tropical Medicine, Liverpool, United Kingdom.
E-mail addresses: chakaya.jm@gmail.com (J. Chakaya), Mishal.Khan@lshtm.ac.uk (M. Khan), fntoumi@fcrm-congo.com (F. Ntoumi), Eleni.Aklillu@ki.se (E. Aklillu),
drraziafatima@gmail.com (R. Fatima), pbmwaba2000@gmail.com (P. Mwaba), nkapata@gmail.com (N. Kapata), gsmfinanga@yahoo.com (S. Mfinanga),
Contents lists available at ScienceDirect
International Journal of Infectious Diseases
journal homepage: www.elsevier .com/ locate / i j idseyedhasnain@gmail.com (S.E. Hasnain), katotopatrick@gmail.com (P.D.M.C. Katoto), andybulabula@gmail.com (A.N.H. Bulabula), nsamagudu@ihvnigeria.org
(N.A. Sam-Agudu), JBN16@pitt.edu (J.B. Nachega), simon.tiberi@nhs.net (S. Tiberi), t.mchugh@ucl.ac.uk (T.D. McHugh), i.abubakar@ucl.ac.uk (I. Abubakar),
a.zumla@ucl.ac.uk (A. Zumla).
https://doi.org/10.1016/j.ijid.2021.02.107
1201-9712/© 2021 The Author(s). Published by Elsevier Ltd on behalf of International Society for Infectious Diseases. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Please cite this article as: J. Chakaya, M. Khan, F. Ntoumi et al., Global Tuberculosis Report 2020 – Reflections on the Global TB burden,
















































J. Chakaya, M. Khan, F. Ntoumi et al. International Journal of Infectious Diseases xxx (xxxx) xxx–xxx
G Model
IJID-5190; No. of Pages 6reatment
revention
Indonesia (8.5%), China (8.4%), the Philippines (6.0%), Pakistan (5.7%), Nigeria (4.4%), Bangladesh (3.6%)
and South Africa (3.6%). Only 30% of the 3.5 million five-year target for children treated for TB was met.
Major advances have been development of new all oral regimens for MDRTB and new regimens for
preventive therapy. In 2020, the COVID-19 pandemic dislodged TB from the top infectious disease cause
of mortality globally. Notably, global TB control efforts were not on track even before the advent of the
COVID-19 pandemic. Many challenges remain to improve sub-optimal TB treatment and prevention
services. Tuberculosis screening and diagnostic test services need to be ramped up. The major drivers of
TB remain undernutrition, poverty, diabetes, tobacco smoking, and household air pollution and these
need be addressed to achieve the WHO 2035 TB care and prevention targets. National programs need to
include interventions for post-tuberculosis holistic wellbeing. From first detection of COVID-19 global
coordination and political will with huge financial investments have led to the development of effective
vaccines against SARS-CoV2 infection. The world now needs to similarly focus on development of new
vaccines for TB utilizing new technological methods.
© 2021 The Author(s). Published by Elsevier Ltd on behalf of International Society for Infectious Diseases.
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-
nd/4.0/).
ntroduction
Every year since 1997, the World Health Organization (WHO)
as published a Global Tuberculosis (TB) report, which provides an
p-to-date assessment of the Global TB situation, and summarizes
rogress and efforts in prevention, diagnosis, and treatment of the
isease, at country, regional and global levels. The 2020 Global TB
eport was released on 14 October 2020 and was compiled in the
ontext of global TB control strategies and United Nations (UN)
argets set in the political declaration at the September 2018 UN
eneral Assembly high-level meeting on TB held in New York. The
ata accounted for over 99% of the world’s population and reported
ata from 198 countries. The 2020 Global TB Report has two
dditional features of note: it complements and elaborates on the
nited Nations (UN) Secretary-General’s 2020 progress report on
B, which was requested in the political declaration at the high-
evel meeting on TB. The report also includes preliminary
ssessments of how the unprecedented corona virus disease
2019 (COVID-19) pandemic may affect TB health services,
reatment and prevention efforts. However, it is important to
ote that global TB control efforts were not on track even before
he advent of the COVID-19 pandemic, and the numerical gap
etween the estimated number of people with TB globally and the
umbers reported to public health authorities remains wide. If all
he missing people with TB, including those from the private
ector, could be identified, the shortfall in reaching all the targets
ight be greater; thus, the failure to reach the targets cannot be
ssumed to be because of the gap between reported and estimated
umbers of people with TB.
In 2019, TB remained the most common cause of death from a
ingle infectious pathogen. Globally, an estimated 10.0 million
eople developed TB disease in 2019, and there were an estimated
.2 million TB deaths among HIV-negative people and an additional
08, 000 deaths among people living with HIV. Adults accounted
or 88% and children, aged <15 years, for 12% of all people with TB.
ost people who developed TB in 2019 were in the WHO regions of
outh-East Asia (44%), Africa (25%), and the Western Pacific (18%),
ith smaller percentages in the Eastern Mediterranean (8.2%), the
mericas (2.9%) and Europe (2.5%). Eight countries accounted for
wo thirds of the global total: India (26%), Indonesia (8.5%), China
8.4%), the Philippines (6.0%), Pakistan (5.7%), Nigeria (4.4%),
angladesh (3.6%) and South Africa (3.6%).
While progress is being made, it has been very slow, and it is
set at 35%, were not reached, with only a 14% change in death rates
achieved between 2015 and 2020. The major constraints are
related to inadequacies in the identification of people-including
children-with TB, for all TB and drug resistant TB in particular,
prevention of TB and financing of the TB response including of
essential TB research. In this paper we highlight the status of TB
care and prevention as presented in the 2020 WHO Global TB
report, outline the persisting constraints, summarize the efforts
that are being made to address these constraints and offer
suggestions on how these efforts can be ramped up.
The gap in finding people with Tuberculosis
Of the 10 million people estimated to have developed TB in
2019, 7.1 million (71%) were identified and reported to national TB
programs around the world, leaving a gap of 2.9 million people
(29%). These missing people with TB include those who were
diagnosed with TB, but were not reported to public health
authorities, (including those not reported from the private sector)
and those who were not diagnosed and therefore not treated. This
pool also includes patients with drug -susceptible or drug-
resistant TB, using current definitions. However, a greater
proportion of people with drug resistant TB are missing: of the
estimated 500,000 people with rifampicin resistant/multidrug-
resistant TB (RR/MDR-TB), only 206, 030 (41%) were identified, as a
result of inadequate testing for drug susceptibility especially
among new people with TB. In 2019, only 57% of people identified
to have pulmonary TB were bacteriologically confirmed, and of
those who were bacteriologically confirmed, only 61% were tested
for RR/MDR-TB, comprising 59% of people not previously treated
for TB and 81% of those who had previously been treated for the
disease. Whilst 206, 030 people with MDR/RR-TB were detected
and notified in 2019, (a 10% increase from 186, 883 in 2018), only
177,099 people were enrolled in treatment, comprising only 38% of
the estimated number of people who developed RR/MDR-TB in
2019.
Another important sub-group of the missing people with TB are
children under 15 years of age. Tuberculosis diagnosis and
treatment gaps are wider among children than adults.
There needs to be a sustained, concerted effort and universal
focus on identifying and treating missing people with TB. WHO
reports that a 50% drop in the number of people with TB detected
could result in up to 400,000 additional TB deaths in a year.nticipated that the world will not end TB as a global public health
hreat by 2035 as envisioned in the End TB Strategy. For example,
hile the target was to reduce TB incidence by 20% between 2015
nd 2020, the 2020 global TB report indicates that there was a
eduction of only 9% in TB incidence in this period, with an annual
eduction of only about 2%. Similarly, mortality reduction targets,2
Governments of high TB endemic countries need to ensure there
are rapid TB diagnostic services available in every health facility, so
all people with TB can be reached. With COVID-19 causing
disruption of health services, many countries have been reported
to be using GeneXpert machines for COVID-19 testing, and others
have reassigned TB programme staff to COVID-19, causing further
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resources. Innovative plans are needed to maintain TB diagnostic
services in the wake of the COVID-19 pandemic (Zumla et al.,
2020). Innovations to adapt TB diagnostic platforms to screen for
both TB and COVID-19, rolling out additional machines, and
investing in development of low-cost rapid diagnostic tests for
both infections are important and urgently needed.
The methods used by the WHO to estimate the global burden of
TB includes the use of data from national prevalence surveys;
notification data adjusted by a standard factor to account for under
-reporting, over - and under diagnosis; inventory studies that
measure under-reporting; and expert opinion on TB detection
gaps. Prevalence surveys, more commonly than not, have shown
that country estimates of prevalence have been lower than what
was observed, consequently, the incidence estimates upon which
the global estimates are based may be lower than what actually
exists. While the methods used to estimate the burden of TB are
continuously being improved, imperfections remain which may
explain the relatively wide uncertainty intervals especially with
country level estimates. Differences in methodological approaches
for the estimation of the burden of TB have in the past led to
significant differences in the estimates of the global burden of TB
provided by the WHO and the Institute for Health Metrics and
Evaluation that undertakes the Global Burden of Disease project
(Garcıa-Basteiro et al., 2018). These methodological challenges in
the estimates of the global burden of TB may have significant
consequences at the programmatic level in countries. National TB
programs may set unrealistically high targets or appear to be
setting unambitious targets if national targets are based on trends
of TB notifications as has been proposed by some experts (Trébucq
and Schwoebel, 2016). We urge the global TB community under the
leadership of the WHO Global Task Force on TB Impact measure-
ment (WHO, 2019) to continue to address this challenge and to
harmonize approaches for the estimation of the burden of TB so
that disease burden estimates become more robust with a more
precise estimate of the size of the TB incidence -detection gap. It is
also equally important to develop robust approaches and tools for
the estimation of the burden of TB at sub-national level where
efforts to identify people with TB are focused as has been proposed
by some countries e.g., Indonesia (Parwati et al., 2020).
Several interventions, many of which have been implemented
to a variable degree in various settings are in place to narrow the TB
incidence-detection gap and excellent reviews have been pub-
lished on this subject (Reid et al., 2019). Some of the major steps
that need to be taken to address the challenge of missing people
with TB at the national and sub-national level in countries include
the identification of TB at risk populations to be targeted to actively
find people with TB, the use of highly sensitive methods for TB
screening and specific TB diagnostic tests (e.g. Xpert MTB/RIF),
linkage to care and treatment of all people identified to have active
TB, measures to ensure retention in care and adherence to
treatment, engagement with communities, development of strong
partnerships with the non-state health sector and ensuring that TB
is an integral component of evolving universal health care
programs. Cascade analysis at all levels of the national TB program
is an effective way of identifying bottlenecks in the pathway to
care, treatment and cure of TB (Subbaraman et al., 2019). The
misalignment of TB services with the places where people seek
health care may be a significant impediment to detection of people
with TB. Alignment of health services would be useful, not only for
adopted and scaled up in each country to ramp up TB detection
efforts and to narrow the TB incidence- notification gap.
The challenge of sub-optimal TB treatment outcomes
The 2020 WHO global TB report contains data on the treatment
outcomes of people treated for drug susceptible TB in 2018 and
those initiated on treatment for drug resistant TB in 2017. Globally
85%, 76% and 57% of people with new and relapse TB, HIV-
associated TB and RR/MDR-TB, respectively, were treated success-
fully. These figures represent a sub-optimal performance. The poor
treatment outcomes are driven mainly by lack of evaluation, poor
linkage to treatment, death and high loss to follow-up. The
underlying causes of poor treatment outcomes include un-
identified or additional drug resistance (Cegielski et al., 2014),
inadequate support provided to people with TB to ensure high level
of adherence, weak recording and reporting systems and inade-
quate prevention and management of advanced HIV disease
including the provision of anti-retroviral treatment. For children
specifically, challenges include under-identification, inadequate
recording and reporting, poor drug formulation options, poor
caregiver availability/capacity for treatment, and persistent issues
with stock out of the few drug options appropriate for this
population. By 2019, only 30% of the 3.5 million five-year target for
children treated for TB had been achieved, including only 8% of the
115,000 target for treatment of children with RR/MDR -TB. Lapses
in data collection and proper and consistent disaggregation
continue to negatively affect identification and treatment as well
as programming and resource-allocation for children under 15
years and adolescents 10-19 years of age.
Based on observational studies in Bangladesh and sub-Saharan
Africa (Bulabula et al., 2019; Trebucq et al., 2018), which were
confirmed by results of the standardised treatment regimen of
anti-TB drugs for people with MDR-TB (STREAM) Stage 1 trial,
WHO now recommends that the shorter 9-month MDR-TB
regimens be preferred as it achieves treatment success in roughly
80% of participants (Nunn et al., 2019). Furthermore, second-line
injectable drugs, if possible, should be replaced by a fully oral,
bedaquiline (BDQ)-containing regimen, one of the new (along with
delamanid and pretomanid) potent MDR-TB drugs that are now
being increasingly prescribed globally. Such regimens should be
urgently scaled-up to improve outcomes, minimize side effects and
improve adherence along with point-of-care molecular drug
susceptibility testing of second line MDR-TB drugs (Bisimwa
et al., 2020; Cox et al., 2018; Diacon et al., 2014; Gler et al., 2012).
Furthermore, attempts have been made in the recent past to
reduce the duration of treatment in drug susceptible TB focused on
the use of fluoroquinolones, however, the large clinical trials that
were undertaken for this purpose failed to demonstrate efficacy for
relapse free cure (Grace et al., 2019). The 2020 Global TB report
includes a comprehensive description of new medicines and
regimens that are at various stages of clinical development and the
reader is urged to consult this document. It is anticipated that
medicines that are currently reserved for the treatment of drug-
resistant TB will soon be available for the treatment of all TB
including TB that is caused by pathogens currently considered to be
drug-susceptible and which have the potential to significantly
shorten treatment. This is exciting and we urge that efforts to
develop new medicines and treatment regimens be ramped up in
line with the ambition that came out of the first ever UnitedTB but for more efficient provision of health care services in
general. Ensuring that a large proportion of the targeted
population is reached with TB screening and diagnostic test
services that is sustained over time has been documented to
reduce the incidence of TB in diverse settings (Corbett et al., 2010;
Kaplan et al., 1972; Marks et al., 2019). Such approaches need to be3
Nations High Level meeting on TB. This will require additional
funding and more robust partnerships between research funders
and research groups. It is particularly important that the global
south where TB is endemic be deeply engaged in all the processes
required for the development of new medicines and regimens for
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n 2006 to commit at least 1% of their Gross Domestic Product to
esearch and development (African Union, 2007).
To ensure that TB treatment is taken as prescribed, directly
bserved of treatment (DOT), has been a pillar of TB care and
revention athough its efficacy compared with self-administered
reatment has been questioned (Volmink and Garner, 2007).
owever, direct observation of TB treatment ingestion may be
isempowering to the person being treated in addition to imposing
emands on that person and the health care system that can be
ifficult to cope with. An approach that is based on providing
omprehensive and individualized support to people being treated
or TB is more likely to be acceptable to people with TB and their
amilies and has been associated with better treatment completion
ates (Alipanah et al., 2018). Furthermore, in the current digital
orld, new ways of supporting people on treatment, including
nteractive two-way mobile phone text message reminders and
ideo assisted DOT have also been associated with good levels of
reatment adherence while providing psychological support
hrough remote counselling (Ngwatu et al., 2018).
ddressing sub-optimal TB prevention
Recent estimates of the global burden of latently infected
ersons with Mycobacterium tuberculosis suggests that 23% (95%
ncertainty interval 20-4%-26.4%) of the global population or
bout 1.7 billion people harbor this infection. This large pool of
atently infected persons is the seedbed of future TB. It has been
stimated that by 2030 and 2050, this pool of latently infected
ersons will generate 16.3 and 8.3 people with active TB per
00,000 population respectively (Houben and Dodd, 2016).
owever, with current and hopefully future diagnostic and
reatment tools most if not all these episodes of TB can be
revented. A major challenge for TB prevention currently is that
here are no easily deployable tools that can identify the subset of
atently infected persons who are likely to progress to active TB.
hile some bio-signatures offer this potential (Sumner et al.,
019) none has been developed to a state that can be used to
upport programs intended to deliver targeted TB preventive
herapy. We urge that this area of research also receives due
ttention, especially funding, to help refine the targeting of TB
reventive therapy as programmatic management of TB preventive
herapy is advanced.
It is noteworthy that progress is being made in the provision of
B preventive therapy even though by 2019, the world was far off
arget. The small successes that are being made, however, need to
e celebrated. For example, in 2019, TB preventive therapy was
rovided to 4.1 million people, which was nearly double the
umber that received this treatment in 2018. For HIV-infected
ndividuals, 85% of those eligible to receive TB preventive therapy
eceived this intervention, which is commendable. While provi-
ion of TB preventive therapy to household contacts of people with
ctive TB remained low, it seems TB programs across the world
ave begun to push forward with this intervention as evidenced by
he increase in the number of household contacts who were
rovided with TB preventive therapy in 2019 (538, 396) compared
o 2018 (423, 607).
The development of new regimens that are shorter and equally
ffective such as a weekly dose of rifapentine and isoniazid for 3
onths (3HP), a daily dose of rifampicin plus isoniazid for 3
have allayed the fears held by some TB program managers and
opinion leaders at the national level, that TB preventive therapy,
using isoniazid preventive therapy could promote the develop-
ment of resistance paving the way for acceleration of TB preventive
therapy. Our view is that this moment should be seized to ensure
TB preventive therapy services are rapidly scaled-up. By doing this
TB preventive therapy, will contribute to the global desire to
accelerate declines in TB incidence.
Preventing future TB must not just be focused on finding and
treating people with TB but should also include efforts to address
social and other determinants of the disease. While efforts are
being made to actively find people with TB and to provide TB
preventive therapy, governments must ensure that the expansion
of economies continues in this COVID-19 era (WHO, 2020) and
percolate to all segments of the populations in every nation. The
major drivers of TB – undernutrition, poverty, diabetes, tobacco
smoking, and household air pollution (Dooley and Chaisson, 2009;
Lee et al., 2020; Noubiap et al., 2019; Reid et al., 2019) must be
addressed if the world is to expect to end TB as a public health
threat by 2035. Moreover, Since the year 2000, WHO has projected
that 54 million people have survived tuberculosis (including a large
proportion of children and adolescents) (Allwood et al., 2020),
however, these people are more likely to develop residual lung
damage and recurrent tuberculosis (Allwood et al., 2019, 2020) and
are at increased risk for all cause-mortality (standardized mortality
ratios: 2.91 (95% CI 2.21-3.84) (Romanowski et al., 2019) compared
with the general population or matched controls. We urge national
TB programs to incorporate post-tuberculosis health and wellbe-
ing interventions in the package of services provided to people
with TB (Chakaya et al., 2016) and encourage the research
community to undertake research intended to unravel the
biomedical and social determinants impacting TB survivals’
long-term prognosis (Romanowski et al., 2019).
It has been over two years since global leaders signed the UN
general assembly high level meeting on TB declaration. It is
disappointing and disheartening that we are not on track to reach
the testing and treatment goals. While global political and public
health systems have been severely shaken by the COVID-19
pandemic, which undoubtedly has dislodged TB from the number
one slot in the year 2020 the expectation is that with the rollout of
COVID-19 vaccines and public health measures, COVID-19 may be
brought under control (Forni and Mantovani, 2021). The long-term
socio-economic effects of the COVID-19 pandemic will further
drive poverty, malnutrition and poor living conditions, which are
risk factors associated with TB prevalence. Thus, TB will likely
quickly re-occupy the number one spot as the most common
infectious cause of mortality worldwide. From first detection of
COVID-19 as a new human pathogen, global coordination and
political will with huge financial investments have led to the
development of effective vaccines against SARS-CoV2 infection
within 11 months. The world now needs to similarly focus on
development of new vaccines for TB utilizing new technological
methods.
We urge the WHO, other UN agencies and partners to develop
mechanisms that strongly push countries to ensure TB multi-
sectoral accountability frameworks are not just developed but are
pursued with vigour. Holistic programs for human development
need to be developed and leaders made to account for their
implementation. Global health inequities driving TB epidemiology,
including the environment and climate control, gender, age, socio-onths (3HR), a daily dose of rifapentine plus isoniazid for 1
onth (1HP), a daily dose of rifampicin for 4 months (4R) (Sterling
t al., 2011; Swindells et al., 2019; WHO, 2020) appeared to have
elped to advance implementation of TB preventive therapy at the
ountry level. We believe that combination therapies such as 3HP,
HR and 1HP have been a truly major advance in that they may4
economic status, and wealth as well as resource distribution,
should also be addressed by multiple approaches and sectors. It is
not yet too late to do this and on the World TB Day 2021, we expect
that every leader and person of influence will get the message that
it is time to reduce inequities as we work towards a TB free world.
While there is a continued need to develop new prevention and
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efficient application of current tools can significantly dent the
burden of TB and advance the push to end TB as a global public
health threat. The time to do this is now.
The world's TB control programs were already failing to meet
the ambitious goals during the past 2-3 years, largely because of
systemic weaknesses. The COVID-19 pandmic and its rapid global
spread, highlights the intrinsic weaknesses of health care systems.
The ultimate generic issue for all communicable diseases of public
health importance is that of creating a systemically strong
healthcare base upon which to build disease-specific programs
such as for TB.
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